PL2044036T3 - Pochodne [4,5']bipirymidynylo-6,4'-diaminy jako inhibitory kinaz białkowych - Google Patents

Pochodne [4,5']bipirymidynylo-6,4'-diaminy jako inhibitory kinaz białkowych

Info

Publication number
PL2044036T3
PL2044036T3 PL07812739T PL07812739T PL2044036T3 PL 2044036 T3 PL2044036 T3 PL 2044036T3 PL 07812739 T PL07812739 T PL 07812739T PL 07812739 T PL07812739 T PL 07812739T PL 2044036 T3 PL2044036 T3 PL 2044036T3
Authority
PL
Poland
Prior art keywords
bipyrimidinyl
protein kinase
diamine derivatives
kinase inhbitors
inhbitors
Prior art date
Application number
PL07812739T
Other languages
English (en)
Inventor
Pamela A Albaugh
Yun He
Songchun Jiang
Pingda Ren
Xia Wang
Xing Wang
Yongping Xie
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PL2044036T3 publication Critical patent/PL2044036T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07812739T 2006-07-12 2007-07-10 Pochodne [4,5']bipirymidynylo-6,4'-diaminy jako inhibitory kinaz białkowych PL2044036T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83049206P 2006-07-12 2006-07-12
EP07812739A EP2044036B1 (en) 2006-07-12 2007-07-10 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors
PCT/US2007/073111 WO2008008747A1 (en) 2006-07-12 2007-07-10 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors

Publications (1)

Publication Number Publication Date
PL2044036T3 true PL2044036T3 (pl) 2011-09-30

Family

ID=38617203

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07812739T PL2044036T3 (pl) 2006-07-12 2007-07-10 Pochodne [4,5']bipirymidynylo-6,4'-diaminy jako inhibitory kinaz białkowych

Country Status (21)

Country Link
US (1) US8026243B2 (pl)
EP (1) EP2044036B1 (pl)
JP (1) JP2009543798A (pl)
KR (1) KR20090029832A (pl)
CN (1) CN101511798B (pl)
AR (1) AR061867A1 (pl)
AT (1) ATE508119T1 (pl)
AU (1) AU2007272646A1 (pl)
BR (1) BRPI0714291A2 (pl)
CA (1) CA2657381A1 (pl)
CL (1) CL2007002017A1 (pl)
DE (1) DE602007014374D1 (pl)
ES (1) ES2367666T3 (pl)
MX (1) MX2009000429A (pl)
PE (1) PE20080548A1 (pl)
PL (1) PL2044036T3 (pl)
PT (1) PT2044036E (pl)
RU (1) RU2009104340A (pl)
TW (1) TW200811134A (pl)
UY (1) UY30477A1 (pl)
WO (1) WO2008008747A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
IN2014CN02475A (pl) 2011-10-06 2015-06-19 Bayer Ip Gmbh
PL2763987T3 (pl) 2011-10-06 2019-01-31 Bayer Cropscience Ag Heterocyklilopiry(mi)dynylopirazole jako środki grzybobójcze
CN106986863B (zh) 2012-04-24 2019-12-31 沃泰克斯药物股份有限公司 Dna-pk抑制剂
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
HK1210500A1 (en) * 2012-09-27 2016-04-22 中外制药株式会社 Fgfr3 fusion gene and pharmaceutical drug targeting same
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
HUE041544T2 (hu) 2013-03-12 2019-05-28 Vertex Pharma DNS-PK inhibitorok
SMT201800127T1 (it) 2013-04-19 2018-05-02 Incyte Holdings Corp Eterocilci biciclici come inibitori di fgfr
WO2015058067A1 (en) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
RU2712222C2 (ru) 2015-03-25 2020-01-27 Нэшнл Кэнсер Сентер Терапевтическое средство против рака желчных протоков
CN115177619A (zh) 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR102613433B1 (ko) * 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
KR102133595B1 (ko) 2019-05-31 2020-07-13 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR102112336B1 (ko) 2019-08-12 2020-05-18 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
CA2539339A1 (en) 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
JP5097539B2 (ja) 2004-05-07 2012-12-12 アムジエン・インコーポレーテツド タンパク質キナーゼ調節剤および使用方法
RU2008135690A (ru) 2006-02-06 2010-03-20 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
KR20090029832A (ko) 2009-03-23
WO2008008747A1 (en) 2008-01-17
CN101511798B (zh) 2011-11-02
EP2044036A1 (en) 2009-04-08
EP2044036B1 (en) 2011-05-04
JP2009543798A (ja) 2009-12-10
RU2009104340A (ru) 2010-08-20
ES2367666T3 (es) 2011-11-07
US20100234376A1 (en) 2010-09-16
MX2009000429A (es) 2009-01-29
PE20080548A1 (es) 2008-06-24
CA2657381A1 (en) 2008-01-17
ATE508119T1 (de) 2011-05-15
DE602007014374D1 (de) 2011-06-16
US8026243B2 (en) 2011-09-27
TW200811134A (en) 2008-03-01
AR061867A1 (es) 2008-09-24
PT2044036E (pt) 2011-08-23
CN101511798A (zh) 2009-08-19
AU2007272646A1 (en) 2008-01-17
CL2007002017A1 (es) 2008-06-13
BRPI0714291A2 (pt) 2014-10-21
UY30477A1 (es) 2009-04-30

Similar Documents

Publication Publication Date Title
PL2044036T3 (pl) Pochodne [4,5']bipirymidynylo-6,4'-diaminy jako inhibitory kinaz białkowych
ZA201202026B (en) PYROLO[2,3-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
ZA200903160B (en) Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
ZA201001434B (en) 2-aza-bicyclo[3.3.0]octane derivatives
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
ZA200810790B (en) Stable laquinimod preparations
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
IL185250A0 (en) Microimplants for ocular administration
EP1858521A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING PROTEINS KINASES
ZA200901268B (en) Substituted imidazolone derivatives, preparation and uses
IL192236A0 (en) Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
IL183140A0 (en) Substituted benzoquinolizine derivatives
IL198239A0 (en) Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a] pyrimidin -6- one and 8-piperidinyl-2- pyrimidinyl [1,2-a] pyrimidin -6- one derivatives
IL191932A0 (en) Hydroxyquinoline derivatives
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200805756B (en) 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivative
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
IL188111A0 (en) 2,5-bis-diamimne [1,4] benzoquinone-derivatives
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS
AU2005904113A0 (en) Garment
AU2005903845A0 (en) Garment
AU2004906082A0 (en) Garment
AU2004902564A0 (en) Garment